Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors

A compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is halogen, cyano, C1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or haloC1-6alkyl;
• m is 0, 1, 2, 3 or 4;
• X is N or CH;
• R2 is halogen, cyano, C1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or haloC1-6alkyl;
• n is 0, 1 or 2;
• W is —CH2—, —CH(C1-6alkyl)- or —C(C1-6alkyl)(C1-6alkyl)-;
• p is 0, 1, 2 or 3;
• Y and Z together form a C3-7cycloalkylene group, or Y is —CH2—, —CH(C1-6alkyl)- or —C(C1-6alkyl)(C1-6alkyl) and Z is —CH2—, —CHOH—, —CHR6— or —CR6R7— (wherein R6 and R7 are independently halogen, cyano, C1-6alkyl or C1-6alkoxy);
• R3 and R4 are independently hydrogen, C1-6alkyl, C1-6alkylsulfonyl or a group having the formula (II):
• wherein
• r is 0, 1, 2, 3 or 4;
• A is oxygen or sulfur;
• B is a single bond or —NR8— (wherein R8 is hydrogen, C1-6alkyl or aryl, wherein the aryl is optionally substituted by one or more substituents independently selected from halogen, oxo, C1-6alkyl, CF3, cyano, hydroxy, C1-6alkanoyl, and C1-6alkoxy);
• D is —(CH2)t—, —(CH2)tO— or —O(CH2)t—, wherein t is 0, 1, 2, 3 or 4;
• and
• E is C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl (optionally substituted by one or more substituents independently selected from halogen, hydroxy, oxo, C1-6alkyl, cyano, CF3, OCF3, C1-6alkoxy and C1-6alkanoyl), aryl (optionally substituted by one or more substituents independently selected from halogen, oxo, C1-6alkyl, CF3, cyano, hydroxy, C1-6alkanoyl and C1-6alkoxy), or E is —NR9R10, wherein R9 and R10 are independently selected from hydrogen, C1-6alkyl and aryl (optionally substituted by one or more substituents independently selected from halogen, oxo, C1-6alkyl, CF3, cyano, hydroxy, C1-6alkanoyl and C1-6alkoxy);
• or R3 and R4, together with the nitrogen atom to which R3 and R4 are attached, form an optionally substituted 3-7 membered monocyclic heterocyclic group or an optionally substituted 8-11 membered bicyclic heterocyclic group, selected from the list consisting of aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isothiazolidinyl, thiazolidinyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, piperidyl, piperazinyl, morpholinyl, thiazinanyl, azepinyl, azepanyl, 6H-thieno[2,3-b]pyrrolyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[5,1-b][1,3]thiazolyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, decahydroquinolinyl, octahydro-2H-1,4-benzoxazinyl, octahydro-1H-cyclopenta[b]pyridinyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, benzoxazinyl, 2,3-dihydro-1,4-benzoxazinyl and benzoazepinyl;
• wherein the heterocyclic groups formed may be substituted by one or more substituents, which may be the same or different, and which are selected from halogen, oxo, C1-6alkyl, cyano, CF3, C1-6alkoxy, C1-6alkanoyl, aryl and arylC1-6alkyl (wherein the aryl and the arylC1-6alkyl are further optionally substituted by halogen, oxo, C1-6alkyl, cyano, CF3, C1-6alkoxy or C1-6alkanoyl);
• and
• R5 is independently halogen, cyano, C1-6alkyl or C1-6alkoxy;
• and
• q is 0, 1, 2, 3 or 4;
• wherein the aryl group is selected from the list consisting of is phenyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, furazanyl, furyl, thienyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, naphthyl, indenyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothienyl, benzuforanyl, dihydrobenzofuranyl, tetrahydrobenzofuranyl, quinolyl, quinoxalinyl, quinazolinyl, isoquinolyl, indazylyl, indanyl, tetrahydronaphthyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, benzoxazinyl and benzoazepinyl.